首页> 美国卫生研究院文献>Materia Socio-Medica >Financial Aspects and the Future of the Pharmaceutical Industry in the United States of America
【2h】

Financial Aspects and the Future of the Pharmaceutical Industry in the United States of America

机译:美利坚合众国的财务状况和制药业的未来

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction:The U.S. pharmaceutical industry is defined by the U.S. Census Bureau as “companies engaged in researching, developing, manufacturing and marketing of medicines and biological for human or veterinary use”. Besides its main role in improving human health, the US pharmaceutical industry represents one of the most critical, key decision makers’ lobbying prone and competitive sectors in the economy. The cost in the environment of very limited government price regulation remains one of the major problems fuelling aggregate health care cost inflation. Pharmaceuticals have created huge benefits for public health and economic productivity by the means of saving lives, increasing life expectancy, reducing illness related suffering, preventing surgeries and decreasing hospital stays.
机译:简介:美国人口普查局将美国制药业定义为“从事研究,开发,生产和销售人类或兽医用药物和生物的公司”。除了在改善人类健康方面的主要作用外,美国制药业还代表着最关键,最关键的决策者之一,游说经济中容易发生变化和具有竞争力的部门。在政府价格监管非常有限的环境下,成本仍然是助长总体医疗保健成本上涨的主要问题之一。药物通过挽救生命,增加预期寿命,减少与疾病有关的痛苦,预防手术和减少住院时间等手段,为公共卫生和经济生产力创造了巨大利益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号